Ar-Rahman Pharm LLC

Warning LetterClosed

Abdur‐Rahmaan Felder Ar-Rahman Pharm LLC 14625 Baltimore Ave., Suite 885 Laurel , MD 20707 United StatesIssued Sep 7, 2021Center for Food Safety and Applied Nutrition (CFSAN)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateSep 7, 2021

Product TypeDrugs

StatusClosed

Closeout LetterMar 21, 2022

Letter Details

Firm: Ar-Rahman Pharm LLC
Location: Abdur‐Rahmaan Felder Ar-Rahman Pharm LLC 14625 Baltimore Ave., Suite 885 Laurel , MD 20707 United States
FEI Number: N/A
Country: United States
Issue Date: September 07, 2021
Issuing Office: Center for Food Safety and Applied Nutrition (CFSAN)
Product Type: Drugs
Status: Closed
Closeout Letter: March 21, 2022

Summary

Ar-Rahman Pharm LLC was cited for marketing an unapproved new drug called "Diabetes Support" as a dietary supplement through their website and social media channels. The company made disease claims including that the product "assists in keeping blood sugar at an optimum level" and "helps to balance blood glucose levels," which violated the Federal Food, Drug, and Cosmetic Act by establishing the product's intended use as a drug without FDA approval. These claims appeared across the company's website (ar-rahmahpharm.com), Instagram, and Facebook pages, and the FDA's review in August 2021 determined the product required either drug approval or removal of all therapeutic claims to comply with regulations.

Ar-Rahman Pharm LLC FDA Warning Letter, September 7, 2021